Please login to the form below
Novartis reveals USD 400m of further cuts
Novartis reveals plans to make additional savings of USD 400m at its pharmaceutical business in addition to the previously announced USD 1bn of cuts
Swiss-based pharmaceutical company Novartis has revealed plans to make additional savings of USD 400m at its pharmaceutical business in addition to the previously announced USD 1bn of cuts, according to local media reports.
The SonntagsZeitung newspaper said that Novartis' head of pharmaceuticals, Thomas Ebeling, had confirmed the new plans in discussions with analysts at the group's Pharma Brand and Business Review on 12 September.
Novartis instituted the cuts to make savings in marketing and sales, where costs rose 11 per cent in 2006.
The newspaper also reported that Novartis was going to make big cuts in its US salesforce after recent product setbacks, after the company expanded it by between 6,000-7,000 in 2006.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
Account Director
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
-
Account Manager
-
£Competitive Salary
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Senior External Communications Lead
-
£Competitive Salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- UK, China prep trials of coronavirus vaccine candidates
- Moderna chairman says COVID-19 vaccine could begin phase 2 trials in spring
- China backs use of Roche’s Actemra for coronavirus
- Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19
- Novartis donates malaria drug for COVID-19 clinical trials
- Moderna and GSK advance coronavirus vaccine candidates
- Incyte and Novartis join coronavirus efforts with phase 3 study
- Moderna chairman says COVID-19 vaccine could begin phase 2 trials in spring
- Merck’s Keytruda beats chemo in first-line colorectal cancer
- “Fake News” and Credibility in Medical Publishing
- How Much Does Each Advisor “Insight” Actually Cost?
- It's not just our logo that's green
PMHub
Creative Medical Research
Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...
Latest intelligence
- “Fake News” and Credibility in Medical Publishing
- Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
- Delivering true value: what does it mean for KAM in cancer care?
- Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
- Pharma funding and M&A in 2020
- Why pharma M&A has continually bucked the trend...
Quick links
Infographics
